Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
Cytomegalovirus (CMV) infection and disease are major complications in the renal transplant recipient. The occurrence of CMV is associated with acute rejection, allograft dysfunction, significant end-organ disease, and mortality. Several clinical studies have indicated that the use of certain immunosuppressive drugs can delay the reconstitution of CMV-specific cell-mediated immune responses, thereby leading to uncontrolled CMV replication. Accumulating evidence indicates, however, that the use of the mammalian target of rapamycin (mTOR) inhibitors, sirolimus, and everolimus, may decrease the incidence and severity of CMV infection in renal transplant recipients. The purpose of this article is to review CMV infection data from randomized clinical trials that investigated the use of sirolimus- and everolimus-based treatment regimens in de novo renal transplantation. The mTOR inhibitor clinical trials included were primarily identified using biomedical literature database searches, with additional studies added at the authors' discretion. This review will summarize these studies to discuss whether mTOR inhibitor-based immunosuppressive therapy can reduce the magnitude of CMV-related complications in the de novo renal transplantation setting.
Department of Hepatobiliary Surgery and Visceral Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany. nashan@uke.uni-hamburg.de
Björn
B
Nashan
Robert
R
Gaston
Vincent
V
Emery
Marcus D
MD
Säemann
Nicolas J
NJ
Mueller
Lionel
L
Couzi
Jacques
J
Dantal
Fuad
F
Shihab
Shamkant
S
Mulgaonkar
Yu
Y
Seun Kim
Daniel C
DC
Brennan
D003587:Cytomegalovirus / Q000187:drug effects; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control*; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000517:prevention & control*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus